Aldeyra Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview

Aldeyra Therapeutics

03/03/2025 21:18

Aldeyra Therapeutics Inc ALDX.OQ ALDX.O is expected to show no change in quarterly revenue when it reports  results on April 30 (estimated) for the period ending March 31 2025

​LSEG's mean analyst estimate for Aldeyra Therapeutics Inc is for a loss of 24 cents per share.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Aldeyra Therapeutics Inc is $10.00​, above​ its last closing price of $5.11. ​​​

This summary was machine generated March 3 at 21:18 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)